The Polybrominated diphenyl ether mixture DE-71 ls. Mildly estrogenic

Minerva Mercado-Feliciano, Robert Bigsby

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment, and they may act as endocrine disruptors. Objective: Our goal in this study was to test the PRIDE Mixture DE-71 for estrogenic activity. Methods: We used proliferation of cultured breast cancer cells (MCF-7) and trophic, effects in the reproductive tracts of ovariectomized mice as estrogen bioassays. DE-71 was administered to mice by subcutaneous injection (sc) or oral gavage (po), alone or in combination with estradiol, for 3 or 34 days. Liver weights and cytochrome P450 enzyme activities were also measured. Results: DE-71 increased MCF-7 cell proliferation, and this was prevented by antiestrogen. DE-71 cotreatment reduced the effect of estradiol in MCF-7 cells. In the mouse 3-day assay, DE-71 administered alone had no effect on uterine weight, uterine epithelial height (UEH), or vaginal epithelial thickness (VET); however, when DE-71 was administered as a cotreatment, it potentiated estradiol's effect on uterine weight. DE-71 administered sc to BALB/c mice for 34 days slightly increased UEH and VET, and attenuated the estradiol-induced increase in UEH; these effects were not seen in BALB/c mice treated po or in C57BL/6 mice treated sc. DE-71 increased liver weight in BALB/c, C57BL/6, and estrogen receptor-α knockout mice. We also found an increase in liver cytochrome P450 1A (CYP1A) and CYP2B activities when DE-71 was administered po, but only CYP2B increased after sc treatment. Conclusion: DE-71 behaves as a weak estrogen. In mice, the treatment route and duration determined if DE-71 was estrogenic, BALB/c mice are more susceptible to DE-71 effects in estrogen target tissues than C57BL/ 6 mice. DE-71 increased liver weight independently of estrogen receptor-α.

Original languageEnglish
Pages (from-to)605-611
Number of pages7
JournalEnvironmental Health Perspectives
Volume116
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Halogenated Diphenyl Ethers
PBDE
cytochrome
Liver
Estradiol
MCF-7 Cells
Weights and Measures
Cytochrome P-450 Enzyme System
endocrine disruptor
Estrogens
Inbred C57BL Mouse
enzyme activity
Estrogen Receptors
pentabromodiphenyl ether
effect
bioassay
cancer
assay
Endocrine Disruptors
Estrogen Receptor Modulators

ASJC Scopus subject areas

  • Environmental Science(all)
  • Environmental Chemistry
  • Public Health, Environmental and Occupational Health

Cite this

The Polybrominated diphenyl ether mixture DE-71 ls. Mildly estrogenic. / Mercado-Feliciano, Minerva; Bigsby, Robert.

In: Environmental Health Perspectives, Vol. 116, No. 5, 05.2008, p. 605-611.

Research output: Contribution to journalArticle

@article{5aa9e3e190274645815ab701f8d78d8a,
title = "The Polybrominated diphenyl ether mixture DE-71 ls. Mildly estrogenic",
abstract = "Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment, and they may act as endocrine disruptors. Objective: Our goal in this study was to test the PRIDE Mixture DE-71 for estrogenic activity. Methods: We used proliferation of cultured breast cancer cells (MCF-7) and trophic, effects in the reproductive tracts of ovariectomized mice as estrogen bioassays. DE-71 was administered to mice by subcutaneous injection (sc) or oral gavage (po), alone or in combination with estradiol, for 3 or 34 days. Liver weights and cytochrome P450 enzyme activities were also measured. Results: DE-71 increased MCF-7 cell proliferation, and this was prevented by antiestrogen. DE-71 cotreatment reduced the effect of estradiol in MCF-7 cells. In the mouse 3-day assay, DE-71 administered alone had no effect on uterine weight, uterine epithelial height (UEH), or vaginal epithelial thickness (VET); however, when DE-71 was administered as a cotreatment, it potentiated estradiol's effect on uterine weight. DE-71 administered sc to BALB/c mice for 34 days slightly increased UEH and VET, and attenuated the estradiol-induced increase in UEH; these effects were not seen in BALB/c mice treated po or in C57BL/6 mice treated sc. DE-71 increased liver weight in BALB/c, C57BL/6, and estrogen receptor-α knockout mice. We also found an increase in liver cytochrome P450 1A (CYP1A) and CYP2B activities when DE-71 was administered po, but only CYP2B increased after sc treatment. Conclusion: DE-71 behaves as a weak estrogen. In mice, the treatment route and duration determined if DE-71 was estrogenic, BALB/c mice are more susceptible to DE-71 effects in estrogen target tissues than C57BL/ 6 mice. DE-71 increased liver weight independently of estrogen receptor-α.",
author = "Minerva Mercado-Feliciano and Robert Bigsby",
year = "2008",
month = "5",
doi = "10.1289/ehp.10643",
language = "English",
volume = "116",
pages = "605--611",
journal = "Environmental Health Perspectives",
issn = "0091-6765",
publisher = "Public Health Services, US Dept of Health and Human Services",
number = "5",

}

TY - JOUR

T1 - The Polybrominated diphenyl ether mixture DE-71 ls. Mildly estrogenic

AU - Mercado-Feliciano, Minerva

AU - Bigsby, Robert

PY - 2008/5

Y1 - 2008/5

N2 - Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment, and they may act as endocrine disruptors. Objective: Our goal in this study was to test the PRIDE Mixture DE-71 for estrogenic activity. Methods: We used proliferation of cultured breast cancer cells (MCF-7) and trophic, effects in the reproductive tracts of ovariectomized mice as estrogen bioassays. DE-71 was administered to mice by subcutaneous injection (sc) or oral gavage (po), alone or in combination with estradiol, for 3 or 34 days. Liver weights and cytochrome P450 enzyme activities were also measured. Results: DE-71 increased MCF-7 cell proliferation, and this was prevented by antiestrogen. DE-71 cotreatment reduced the effect of estradiol in MCF-7 cells. In the mouse 3-day assay, DE-71 administered alone had no effect on uterine weight, uterine epithelial height (UEH), or vaginal epithelial thickness (VET); however, when DE-71 was administered as a cotreatment, it potentiated estradiol's effect on uterine weight. DE-71 administered sc to BALB/c mice for 34 days slightly increased UEH and VET, and attenuated the estradiol-induced increase in UEH; these effects were not seen in BALB/c mice treated po or in C57BL/6 mice treated sc. DE-71 increased liver weight in BALB/c, C57BL/6, and estrogen receptor-α knockout mice. We also found an increase in liver cytochrome P450 1A (CYP1A) and CYP2B activities when DE-71 was administered po, but only CYP2B increased after sc treatment. Conclusion: DE-71 behaves as a weak estrogen. In mice, the treatment route and duration determined if DE-71 was estrogenic, BALB/c mice are more susceptible to DE-71 effects in estrogen target tissues than C57BL/ 6 mice. DE-71 increased liver weight independently of estrogen receptor-α.

AB - Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment, and they may act as endocrine disruptors. Objective: Our goal in this study was to test the PRIDE Mixture DE-71 for estrogenic activity. Methods: We used proliferation of cultured breast cancer cells (MCF-7) and trophic, effects in the reproductive tracts of ovariectomized mice as estrogen bioassays. DE-71 was administered to mice by subcutaneous injection (sc) or oral gavage (po), alone or in combination with estradiol, for 3 or 34 days. Liver weights and cytochrome P450 enzyme activities were also measured. Results: DE-71 increased MCF-7 cell proliferation, and this was prevented by antiestrogen. DE-71 cotreatment reduced the effect of estradiol in MCF-7 cells. In the mouse 3-day assay, DE-71 administered alone had no effect on uterine weight, uterine epithelial height (UEH), or vaginal epithelial thickness (VET); however, when DE-71 was administered as a cotreatment, it potentiated estradiol's effect on uterine weight. DE-71 administered sc to BALB/c mice for 34 days slightly increased UEH and VET, and attenuated the estradiol-induced increase in UEH; these effects were not seen in BALB/c mice treated po or in C57BL/6 mice treated sc. DE-71 increased liver weight in BALB/c, C57BL/6, and estrogen receptor-α knockout mice. We also found an increase in liver cytochrome P450 1A (CYP1A) and CYP2B activities when DE-71 was administered po, but only CYP2B increased after sc treatment. Conclusion: DE-71 behaves as a weak estrogen. In mice, the treatment route and duration determined if DE-71 was estrogenic, BALB/c mice are more susceptible to DE-71 effects in estrogen target tissues than C57BL/ 6 mice. DE-71 increased liver weight independently of estrogen receptor-α.

UR - http://www.scopus.com/inward/record.url?scp=45749107831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749107831&partnerID=8YFLogxK

U2 - 10.1289/ehp.10643

DO - 10.1289/ehp.10643

M3 - Article

C2 - 18470304

AN - SCOPUS:45749107831

VL - 116

SP - 605

EP - 611

JO - Environmental Health Perspectives

JF - Environmental Health Perspectives

SN - 0091-6765

IS - 5

ER -